Earnings summaries and quarterly performance for Travere Therapeutics.
Executive leadership at Travere Therapeutics.
Board of directors at Travere Therapeutics.
Research analysts who have asked questions during Travere Therapeutics earnings calls.
LC
Laura Chico
Wedbush Securities
6 questions for TVTX
Also covers: APLS, ARDX, BCRX +11 more
Jason Zemansky
Bank of America
5 questions for TVTX
Also covers: ABOS, BBIO, CYTK +5 more
Prakhar Agrawal
Cantor Fitzgerald
5 questions for TVTX
Also covers: ARDX, ARWR, IMVT +5 more
SR
Sadia Rahman
Wells Fargo
4 questions for TVTX
Also covers: AMGN, HALO, MLYS
TV
Tyler Van Buren
TD Cowen
4 questions for TVTX
Also covers: ADVM, ALLO, ARGX +13 more
Vamil Divan
Guggenheim Securities
4 questions for TVTX
Also covers: ABBV, ABSI, ANIP +7 more
YN
Yigal Nochomovitz
Citigroup Inc.
4 questions for TVTX
Also covers: ALDX, APLS, ARCT +22 more
Alex Thompson
Stifel Financial Corp.
3 questions for TVTX
Also covers: ARGX, ASND, CRNX +3 more
AR
Anupam Rama
JPMorgan Chase & Co.
3 questions for TVTX
Also covers: APLS, BBIO, BOLD +18 more
MR
Maury Raycroft
Jefferies
3 questions for TVTX
Also covers: ABEO, ALNY, ARWR +14 more
WS
Will Soghikian
Leerink Partners
3 questions for TVTX
Also covers: AUPH, KALV, RARE
Arseniy Shabashvili
Guggenheim Securities
2 questions for TVTX
Also covers: ABSI
Gavin Clark-Gartner
Evercore ISI
2 questions for TVTX
Also covers: ACRS, ARGX, ASND +12 more
Gregory Harrison
Scotiabank
2 questions for TVTX
Also covers: AGIO, APLS, EYPT +3 more
JS
Joe Schwartz
Leerink Partners
2 questions for TVTX
Also covers: BMRN, CRNX, INSM +3 more
Liisa Bayko
Evercore ISI
2 questions for TVTX
Also covers: ALT, BCRX, INSM +7 more
Mohit Bansal
Wells Fargo & Company
2 questions for TVTX
Also covers: ABBV, AMGN, BMRN +16 more
Priyanka Grover
JPMorgan Chase & Co.
2 questions for TVTX
Also covers: DAWN, FOLD, SNDX +1 more
Alexander Thompson
Stifel
1 question for TVTX
Also covers: ACRS, ARGX, ASND +5 more
Charles Ndiaye
Stifel Financial Corp.
1 question for TVTX
Also covers: KYMR
DR
Dina Ramadane
Bank of America
1 question for TVTX
Also covers: BLUE, PCVX, RPRX +1 more
EA
Ed Arce
WestPark Capital
1 question for TVTX
Also covers: ABUS, AKBA, ARCT +5 more
Farzin
Jefferies
1 question for TVTX
Farzin Haque
Jefferies
1 question for TVTX
Also covers: ABEO, ARWR, AUPH +3 more
FD
Frances Dovell
TD Cowen
1 question for TVTX
Also covers: CELC, CRNX, LNTH
GW
Greg Wiessner
TD Cowen
1 question for TVTX
Also covers: MRNA
Joe Thomas
Scotiabank
1 question for TVTX
Also covers: APLS, OCUL
JS
Joseph Schwartz
Oppenheimer
1 question for TVTX
Also covers: ASND, AUPH, BMRN +14 more
JT
Joseph Thomas
HSBC
1 question for TVTX
Also covers: FLUT
MR
Maurice Raycroft
Jefferies Financial Group
1 question for TVTX
Also covers: ABEO, AFMD, ALNY +14 more
R
Reena
Citigroup Inc.
1 question for TVTX
Recent press releases and 8-K filings for TVTX.
Travere Therapeutics Reports Strong Q4 2025 Results and Updates on FILSPARI and Pipeline
TVTX
Earnings
Product Launch
Revenue Acceleration/Inflection
- Travere Therapeutics reported U.S. net product sales of $126.6 million for Q4 2025 and $410.5 million for the full year 2025. FILSPARI net product sales grew 144% year-over-year to $322 million for FY 2025, with $103.3 million in Q4 2025. The company achieved a net income of $2.7 million for Q4 2025.
- FILSPARI demonstrated strong momentum in IgA nephropathy (IgAN) with record demand of 908 new patient starts in Q4 2025. The company anticipates meaningful net product sales growth for FILSPARI in IgAN in 2026 and projects peak sales potential above $1 billion for this indication.
- The FDA's PDUFA target action date for the sNDA for FILSPARI in FSGS is now April 13, 2026, following a major amendment. Travere believes this indication, if approved, represents a meaningful opportunity with potentially more rapid uptake than IgAN.
- Travere is advancing pegtibatinase for classical homocystinuria (HCU), having recently resumed site activation for its pivotal Phase 3 HARMONY study.
Feb 19, 2026, 9:30 PM
Travere Therapeutics Reports Strong Q4 and Full-Year 2025 Sales, Provides Pipeline Updates
TVTX
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Travere Therapeutics reported ~$103 million in U.S. net FILSPARI sales for Q4 2025, representing ~108% growth year-over-year, contributing to ~$410 million in total U.S. net product sales for fiscal year 2025, an ~81% growth year-over-year.
- The company maintained a strong financial position with ~$323 million in cash and cash equivalents as of December 31, 2025, and retired $69 million in convertible notes.
- Key pipeline updates include the FDA extending the review period for FILSPARI's sNDA for traditional approval in FSGS, setting a new Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. Additionally, enrollment activities for the Phase 3 HARMONY Study of pegtibatinase for HCU resumed in Q1 2026, following manufacturing optimization in 2025.
- Travere Therapeutics operates in a rare kidney and metabolic diseases market projected to exceed $10 billion, with significant addressable patient populations including >70,000 IgAN patients and up to 30,000 FSGS patients in the U.S..
Feb 19, 2026, 9:30 PM
Travere Therapeutics Reports Strong Q4 and Full-Year 2025 Results, Updates on FILSPARI FSGS PDUFA Date
TVTX
Earnings
Guidance Update
New Projects/Investments
- Travere Therapeutics reported Q4 2025 U.S. net product sales of $126.6 million and full-year 2025 total net product sales of $410.5 million, with FILSPARI net product sales reaching $322 million for the full year, representing 144% year-over-year growth.
- The company achieved net income of $2.7 million (or $0.03 per basic share) in Q4 2025, a significant improvement from a net loss in the prior year, and ended the year with $322.8 million in cash, cash equivalents, and marketable securities.
- The FDA PDUFA target action date for FILSPARI's supplemental New Drug Application (sNDA) for Focal Segmental Glomerulosclerosis (FSGS) has been set for April 13, 2026, following a major amendment and additional information requests.
- Travere is advancing its pipeline, having resumed site activation for the pivotal Phase 3 HARMONY study of pegtibatinase for classical homocystinuria (HCU), which has the potential to be the first disease-modifying medicine for the condition.
Feb 19, 2026, 9:30 PM
Travere Therapeutics Reports Strong Q4 and Full-Year 2025 Results, FILSPARI Sales Up 144% Year-Over-Year
TVTX
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Travere Therapeutics reported Q4 2025 U.S. net product sales of $126.6 million and full-year 2025 total net product sales of $410.5 million, with FILSPARI sales reaching $322 million for the full year, representing 144% year-over-year growth.
- The company achieved net income of $2.7 million or $0.03 per basic share in Q4 2025, a significant improvement from a net loss in Q4 2024, and maintained a strong financial position with $322.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
- FILSPARI demonstrated record demand of 908 new patient starts in Q4 2025 for IgA nephropathy, with strong demand continuing into Q1 2026, and is expected to deliver robust growth as a foundational therapy with a peak potential well above $1 billion for this indication alone.
- The FDA's PDUFA target action date for FILSPARI's sNDA for an FSGS indication is now April 13, 2026, following a major amendment, and Travere has expanded its commercial team to over 100 field personnel in anticipation of a potential approval, viewing FSGS as a potentially larger opportunity with more rapid uptake.
- Beyond FILSPARI, Travere is advancing pegtibatinase for classical homocystinuria (HCU), having recently resumed site activation for its pivotal phase 3 HARMONY study to enable global enrollment.
Feb 19, 2026, 9:30 PM
Travere Therapeutics Reports Q4 and Full Year 2025 Financial Results
TVTX
Earnings
Product Launch
New Projects/Investments
- Travere Therapeutics reported U.S. net product sales of $126.6 million for the fourth quarter of 2025 and $410.5 million for the full year 2025.
- FILSPARI U.S. net product sales reached $103.3 million in Q4 2025, marking 108% growth over the prior year period, and totaled $322.0 million for full year 2025, representing 144% growth.
- The company achieved net income of $2.7 million for the fourth quarter of 2025, or $0.03 per basic share, and a net loss of $25.5 million for the full year 2025, or $0.29 per basic share.
- The PDUFA target action date for FILSPARI in FSGS is April 13, 2026, with the company positioned for a successful commercial launch if approved. Enrollment activities have also resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU.
- As of December 31, 2025, Travere Therapeutics had $322.8 million in cash, cash equivalents, and marketable securities.
Feb 19, 2026, 9:05 PM
Travere Therapeutics Reports Q4 and Full Year 2025 Financial Results
TVTX
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Travere Therapeutics reported U.S. net product sales of $410.5 million for the full year 2025, with FILSPARI sales totaling $322.0 million, representing 144% growth versus full year 2024.
- For the fourth quarter of 2025, the company achieved net income of $2.7 million, compared to a net loss of $60.3 million for the same period in 2024.
- As of December 31, 2025, Travere Therapeutics had $322.8 million in cash, cash equivalents, and marketable securities.
- The PDUFA target action date for FILSPARI in FSGS is April 13, 2026, and enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU.
Feb 19, 2026, 9:01 PM
Travere Therapeutics Provides Updates on FILSPARI Regulatory Review, Commercial Performance, and Pipeline Progress
TVTX
Product Launch
New Projects/Investments
Guidance Update
- Travere Therapeutics is awaiting an FDA decision on its sNDA for FILSPARI in FSGS, with a PDUFA date of April 13th, 2026, following a recent extension due to additional information requests from the FDA. The company expresses high confidence in approval.
- The company reported its strongest quarter to date for FILSPARI in IgA nephropathy, with continued growth and increasing awareness of the need for treatment. They anticipate faster uptake for FILSPARI in FSGS compared to IgAN due to expected full approval, quarterly REMS, and high unmet need.
- The Phase III HARMONY study for pegtibatinase in homocystinuria (HCU) is restarting this quarter after resolving manufacturing challenges, with expectations for quick enrollment given the significant unmet need and lack of clinical development competitors.
- Travere Therapeutics ended the year with $323 million in cash, indicating no near-term capital needs to support its priorities. The base case for FILSPARI's patent estate extends to 2033, with potential for further extension.
Feb 11, 2026, 9:00 PM
Travere Therapeutics Provides Updates on FILSPARI FSGS PDUFA and Pegtibatinase Study Restart
TVTX
Product Launch
New Projects/Investments
- Travere Therapeutics is focused on rare diseases, with significant progress in IgA nephropathy, FSGS, and homocystinuria (HCU).
- The PDUFA date for FILSPARI in FSGS is set for April 13, 2026, following an FDA extension due to additional information requests, with the company expressing high confidence in approval and anticipating rapid market uptake.
- The Phase III HARMONY study for pegtibatinase in HCU is scheduled to restart in Q1 2026, after successfully resolving manufacturing scale-up issues.
- The company ended 2025 with $323 million in cash and projects FILSPARI's base case patent protection to 2033, with ongoing efforts to extend it further.
Feb 11, 2026, 9:00 PM
Travere Therapeutics Discusses Strong FILSPARI Performance and Upcoming FSGS PDUFA
TVTX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Travere Therapeutics reported its strongest quarter to date for FILSPARI in IgA nephropathy, establishing it as foundational care.
- The FDA's PDUFA date for FILSPARI in FSGS is set for April 13th, following an sNDA extension; management maintains high confidence in approval and anticipates rapid uptake.
- The Phase III HARMONY study for pegtibatinase in homocystinuria (HCU) is scheduled to restart this quarter after resolving manufacturing challenges.
- The company concluded the year with $323 million in cash, indicating sufficient capital to support its key programs without near-term financing needs.
- FILSPARI's patent estate is expected to last until at least 2033, with potential for further extension.
Feb 11, 2026, 9:00 PM
Travere Therapeutics Announces FDA Extends FILSPARI Review for FSGS
TVTX
Product Launch
New Projects/Investments
- The FDA has extended the review timeline for Travere Therapeutics' supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), with a new Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026.
- This extension follows the submission of responses requested by the FDA, which were determined to constitute a Major Amendment to the sNDA.
- Travere Therapeutics is continuing commercial launch preparations for FILSPARI in FSGS, anticipating potential approval for what would be the first medication indicated for this rare and serious kidney disorder.
Jan 13, 2026, 6:24 PM
Quarterly earnings call transcripts for Travere Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more